Department of Respiratory Medicine, University Hospital of Patras

20/09/2022

A bivalent vaccine with sequences from Wuhan-Hu-1 and omicron BA.1, given as a booster to previously vaccinated persons, was immunogenic in 100% of recipients, with higher levels of neutralizing antibodies against BA.4/BA.5 than a Wuhan-Hu-1 booster.

Original Article from The New England Journal of Medicine — A Bivalent Omicron-Containing Booster Vaccine against Covid-19

30/05/2022

Σας περιμένουμε για ενα εποικοδομητικό τριήμερο

18/02/2022

https://www.nejm.org/doi/full/10.1056/NEJMoa2118542?fbclid=IwAR39rTFTNKUGHUjRo90ZhzBBqzf5cP6xbaBj_BvO2qBDfzyFmm-q4E12wrQ

Original Article from The New England Journal of Medicine — Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

23/01/2022

Heterologous boosting after two doses of CoronaVac COVID-19 vaccine results in more robust immune responses than homologous boosting, study suggests:

Antibody concentrations were low at 6 months after previous immunisation with two doses of CoronaVac. However, all four vaccines administered as a third dose induced a significant increase in binding and neutralising antibodies, which could improve protection against infection. Heterologous boosting...

01/01/2022

Thrombotic events complicate COVID-19 but there is no consensus on the use of extended thromboprophylaxis beyond the hospital stay.

A new trial suggests in patients at high risk discharged after COVID-19 hospitalisation, thromboprophylaxis with rivaroxaban 10 mg/day for up to 35 days improved clinical outcomes, reducing thrombotic events compared with no post-discharge anticoagulation.

Full study and linked Comment:

In patients at high risk discharged after hospitalisation due to COVID-19, thromboprophylaxis with rivaroxaban 10 mg/day for 35 days improved clinical outcomes compared with no extended thromboprophylaxis.

30/12/2021

Receipt of three vaccine doses led to better neutralization of the wild-type virus and the three variants than receipt of two vaccine doses. The geometric mean titers of the wild-type virus and the beta, delta, and omicron variants were 16.56, 1.27, 8.00, and 1.11, respectively, after receipt of the second vaccine dose and 891.4, 152.2, 430.5, and 107.6, respectively, after receipt of the third dose.

Correspondence from The New England Journal of Medicine — Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection

24/12/2021

Administration of tocilizumab, at the time point that PaO2/FiO2 < 200 was observed, improved survival and other clinical outcomes in hospitalized patients with severe COVID-19 irrespective of systemic inflammatory markers levels.

Background Data on the safety and efficacy profile of tocilizumab in patients with severe COVID-19 needs to be enriched. Methods In this open label, prospective study, we evaluated clinical outcomes in consecutive patients with COVID-19 and PaO2/FiO2 < 200 receiving tocilizumab plus usual care v...

22/12/2021

https://www.nejm.org/doi/full/10.1056/NEJMoa2116846?fbclid=IwAR0z6jcovEbPWHXfDFPG_RPrPBaecX_Lzk8Rig7rK9JruxOIDYZemymrF8M

Original Article from The New England Journal of Medicine — Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

08/09/2021

ERS 2021
Department of Respiratory Medicine, University of Patras

10/07/2021

Does slow vital capacity (SVC) instead of FVC increase the sensitivity of spirometry to identify patients with early or mild obstructive lung disease?

Low FEV1 to SVC in current and former smokers with normal spirometry results can identify individuals with CT scan features of COPD who are at risk for severe exacerbations and is associated with progression to COPD in the future.

Low FEV1 to SVC in current and former smokers with normal spirometry results can identify individuals with CT scan features of COPD who are at risk for severe exacerbations and is associated with progression to COPD in the future.